(Total Views: 416)
Posted On: 11/21/2025 10:49:31 PM
Post# of 158792
Re: sherlock57 #158594
-"how do they define "disease progression" in solid tumor trials"?
im not sure how they define it. But there must be a way they will know the general time frame to initiate the rollover if thats the decision. ( maybe just no additional shrinkage?)
"Your group for the dose of leronlimab will be assigned once you are enrolled in the trial.
You will take a once weekly dose (subcutaneous injection) of leronlimab in combination with trifluridine + tipiracil (LONSURF®/TAS-102) + bevacizumab until your **cancer no longer responds** or until you get unacceptable side effects.
Leronlimab will be injected weekly via a very thin needle slightly below the surface of your skin in your stomach, by the research staff or visiting nurse. After the completion of one full cycle (4 weeks) participants will have the option of administering leronlimab at home on Day 8 (week 2) and Day 22 (week 4) of each subsequent cycle either by self-administration or by a caregiver after being trained to do so by the study staff".
https://www.foxchase.org/clinical-care/clinic...als/search
> Leronlimab
im not sure how they define it. But there must be a way they will know the general time frame to initiate the rollover if thats the decision. ( maybe just no additional shrinkage?)
"Your group for the dose of leronlimab will be assigned once you are enrolled in the trial.
You will take a once weekly dose (subcutaneous injection) of leronlimab in combination with trifluridine + tipiracil (LONSURF®/TAS-102) + bevacizumab until your **cancer no longer responds** or until you get unacceptable side effects.
Leronlimab will be injected weekly via a very thin needle slightly below the surface of your skin in your stomach, by the research staff or visiting nurse. After the completion of one full cycle (4 weeks) participants will have the option of administering leronlimab at home on Day 8 (week 2) and Day 22 (week 4) of each subsequent cycle either by self-administration or by a caregiver after being trained to do so by the study staff".
https://www.foxchase.org/clinical-care/clinic...als/search
> Leronlimab
(1)
(0)
